Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH MEDIA
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC

Reduced Elafin Levels Associated with Celiac Disease Bowel Inflammation

By BiotechDaily International staff writers
Posted on 22 Apr 2014
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).
Image: Biopsy of small bowel showing celiac disease manifested by blunting of villi, crypt hyperplasia, and lymphocyte infiltration of crypts (Photo courtesy of Wikimedia Commons).
Levels of the enzyme elafin, an endogenous serine protease inhibitor, were lower in the small intestinal epithelium of patients with active celiac disease (CD) as compared to similar tissue from control patients.

Celiac disease is an immune disorder that occurs in susceptible individuals when foods that contain gluten and its derivative, the highly immunogenic gliadin peptide, trigger an immune response that leads to destruction of the intestinal lining, abdominal pain, changes in bowel habits, malnutrition and other symptoms that include anemia and neurological problems.

Investigators at McMaster University (Hamilton, ON, Canada) used immunofluorescence techniques to examine the role of elafin in CD using tissues taken from human small intestines. The degree of deamidation of the 33-mer gliadin peptide was analyzed by liquid chromatography-mass spectrometry. To study the effects of elafin on a mouse model of celiac disease, the protein was delivered to the intestine of gluten-sensitive mice using a recombinant Lactococcus lactis vector.

Results published in the April 8, 2014, online edition of the American Journal of Gastroenterology revealed that elafin expression in the small intestinal epithelium was lower in patients with active CD compared with control patients. In vitro, elafin significantly slowed the kinetics of the deamidation of the 33-mer peptide to its more immunogenic form. Treatment of gluten-sensitive mice with elafin delivered by the L. lactis vector normalized inflammation and improved permeability.

Maintaining a gluten-free diet is far from simple, as gluten is found not only in foods but as low cost filler in the cosmetic and pharmaceutical industries as well.

“People who have to strictly avoid gluten for life often find this very difficult due to these hidden sources,” said senior author Dr. Elena Verdu, associate professor of medicine at McMaster University. “There is a great need for a therapy that will protect patients with celiac disease from these accidental contaminations. The possibility of elafin administration or replacement as a new adjuvant therapy to the gluten free diet would add flexibility to a restrictive lifelong diet, and increase patients’ quality of life and potentially accelerate the healing of celiac lesions.”

Related Links:

McMaster University



WATERS CORPORATION

Channels

Drug Discovery

view channel
Image: Molecular model of the anti-cancer drug 5-fluorouracil (Photo courtesy of Wikimedia Commons).

Novel Microcapsule Approach Reduces Toxic Side Effects of Chemotherapy

Cancer researchers have reduced chemotherapy's toxic side effects by using nanoporous capsules to transport an enzyme to the site of a tumor where it is activated by a selective heating process to convert... Read more

Lab Technologies

view channel
Image: The gene assembly robot, the GeneTheatre (Photo courtesy of Analytik Jena AG).

Genomic Research Laboratories Await New Compact Liquid Handling System

A small footprint benchtop liquid handler that automates multiple gene assembly tasks and associated procedures such as PCR setup is now available for use by biotech and genomic research laboratories.... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 

Events

02 Jun 2015 - 03 Jun 2015
15 Jun 2015 - 18 Jun 2015
Copyright © 2000-2015 Globetech Media. All rights reserved.